EUVIMEDEUVIMED entdecken
Crossref

Short-term methotrexate plus cyclosporine for graft-versus-host disease prophylaxis after single-unit cord blood transplantation following reduced-intensity conditioning

Takeshi Sugio, Koji Kato, Shuro Yoshida, Noriyuki Saito, Ichiro Kawano, Hideho Henzan, Toshihiro Miyamoto, Koichi Akashi, Tetsuya Eto

Japanese Journal of Transplantation and Cellular Therapy · 2022

DOI: 10.7889/tct-21-001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Transplantation and Cellular Therapy, 2022. Verfasst von Takeshi Sugio und 8 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cord blood is an alternative donor source for patients without HLA-matched donors. Calcineurin inhibitors (CNIs) alone, as prophylaxis for graft-versus-host disease (GVHD) in cord blood transplantation (CBT) patients, reportedly increase the incidence of severe pre-engraftment immune reaction (PIR), leading to transplant-related mortality (TRM) with primary engraft failure and multiple organ dysfunctions. Therefore, additional immunosuppressive agents are needed. Reportedly, short-term methotrexate (sMTX) plus CNIs improved outcomes in patients receiving CBT with full-intensity conditioning (FIC) regimens; however, safety and efficacy of sMTX plus cyclosporine have not been assessed in patients receiving CBT with reduced-intensity conditioning (RIC) regimens.

Methods

We retrospectively analyzed 43 patients who received single-unit CBT and were treated with sMTX plus cyclosporine (RIC group, 15; FIC group, 28).

Results

Neutrophil engraftment rate was significantly lower in RIC group (53.3%) than in FIC group (78.6%, P=0.04). Cumulative incidence of TRM tended to be higher in the RIC group than in the FIC group (P=0.12); the leading cause of death in the RIC group was bacterial infections. Conclusions: sMTX plus cyclosporine does not seem feasible for treating patients receiving single-unit CBT following RIC. MTX dose optimization or alternative immunosuppressive agent application should be considered in such patients.

Zitieren

APA

Sugio, T., Kato, K., Yoshida, S., Saito, N., Kawano, I., Henzan, H., Miyamoto, T., Akashi, K., & Eto, T. (2022). Short-term methotrexate plus cyclosporine for graft-versus-host disease prophylaxis after single-unit cord blood transplantation following reduced-intensity conditioning. Japanese Journal of Transplantation and Cellular Therapy. https://doi.org/10.7889/tct-21-001

Vancouver

Sugio T, Kato K, Yoshida S, Saito N, Kawano I, Henzan H, et al. Short-term methotrexate plus cyclosporine for graft-versus-host disease prophylaxis after single-unit cord blood transplantation following reduced-intensity conditioning. Japanese Journal of Transplantation and Cellular Therapy. 2022. doi:10.7889/tct-21-001

BibTeX
@article{Sugio2022,
  author = {Sugio, Takeshi and Kato, Koji and Yoshida, Shuro and Saito, Noriyuki and Kawano, Ichiro and Henzan, Hideho and Miyamoto, Toshihiro and Akashi, Koichi and Eto, Tetsuya},
  title = {Short-term methotrexate plus cyclosporine for graft-versus-host disease prophylaxis after single-unit cord blood transplantation following reduced-intensity conditioning},
  journal = {Japanese Journal of Transplantation and Cellular Therapy},
  year = {2022},
  doi = {10.7889/tct-21-001}
}
Kostenlos starten →